Gene therapy firms face manufacturing and regulatory challenges that slow development and limit patient access. The good news is that new technologies have the potential to resolve many of these difficulties.
GAITHERSBURG, Md., March 22, 2022 /PRNewswire/ MaxCyte, Inc., (NASDAQ: MXCT) (LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies